## **HEALEY ALS Platform Trial**

Weekly Q&A - Aug 19, 2021













BARROW

Neurological Institute\*



### **Healey Center**

Sean M. Healey & AMG Center for ALS at Mass General





































## **Guest Speaker**

Laura Foster, MD
University of Colorado Anschutz, CO
Platform Trial Site Investigator





#### **University of Colorado – Healey ALS Platform Trial Research Team**



Laura Foster, MD
Assistant Professor



Stacy Dixon, MD, PhD

Assistant Professor




Brianna Blume, MS, CCRP
Neuromuscular Research Development
Program Manager



Brenna Baines, BS Clinical Research Coordinator



Haley Simpson, BS
Clinical Research
Recruitment Specialist
& Coordinator



Emily Hyslop, BA
Clinical
Research
Coordinator



Diana Santacruz, BS Clinical Research Coordinator





# **CU's participation in the Healey ALS Platform Trial**

- Well-established research team
- First participant enrolled October 2020
- 14 participants (as of Aug 18, 2021)



**CU** study visit sites





## How to help screening process


- Tell us about every medication or supplement, including over-the counter products
- Know where prior medical records are

## **Travel tips**

- Bring a travel buddy
- Bring snacks
- Stay at a hotel nearby



#### Perpetual Adaptive Trial Shared Placebo; Randomization Ratio 3:1 Open Label Extension (OLE) offered



## Enrollment Updates (as of August 19, 2021)


- 705 individuals with ALS signed informed consent
- 558 individuals were assigned to a regimen
- 510 individuals were randomized within a regimen (active or placebo)
- 180 have entered the Open Label Extension (OLE)

Total randomized + Participants in screening

- 139 individuals were randomized within Regimen A = 150
- 154 individuals were randomized within Regimen B = 157
- 155 individuals were randomized within Regimen C = 158
- 62 individuals were randomized within Regimen D = 67



#### How to Find a Center Near You



52 sites are actively enrolling

Contact Info of Participating Sites by State



https://www.massgeneral.org/neurology/als/research/platform-trial-sites

## **Patient Navigator**



# Catherine Small Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu



To see whether you might qualify, view the list of eligibility criteria:

https://bit.ly/3p4PrLL



#### Send us webinar ideas!

- Biomarkers
- Biostatistics / Trial Design
- Get to know our sites





#### **Upcoming Guest Speakers:**

Aug 26<sup>th</sup>- Niraja Suresh, MD (University of South Florida, FL) Sept 2<sup>nd</sup>- Terry Heiman-Patterson, MD (Temple University, PA) Sept 9<sup>th</sup>- Jennifer DiMartino (Executive Director, ALS ONE) Sept 16<sup>th</sup>- No webinar this week in observance of Yom Kippur Sept 23<sup>rd</sup>- Namita Goyal, MD (University of CA Irvine, CA)

### For More Updates

Weekly webinars

The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have

Find the schedule and registration links on our website

https://www.massgeneral.org/neurology/als/research/platform-trial-news/

#### Previously: Drug mechanism of action and science webinars



Jan 21- Prilenia/Pridopidine

Feb 4 - Clene/CNM-Au8

Feb 25- UCB/Zilucoplan

(<u>recorded</u>- https://bit.ly/3ad3qel)

(recorded- https://bit.ly/3jB3WWt)

Feb 18- Biohaven/Verdiperstat (recorded- https://bit.ly/301qdDR)

(recorded- https://bit.ly/3b3cpyS)